Nordic Nanovector to terminate Phase IIb follicular lymphoma trial
The company will now shift the focus on the development of its pipeline of CD37-targeting products.
Norway
Latest in
Norway
Ultimovacs Phase II melanoma trial concludes subject recruitment
The trial will analyse the combination therapy as a first-line treatment in advanced or metastatic malignant melanoma patients.
Ultimovacs’ cancer vaccine demonstrates overall survival in Phase I melanoma trial
The 24-month survival rate was reported to be 73% across all 30 subjects in the trial.
Nykode concludes subject enrolment in Phase II cervical cancer vaccine trial
The multicentre, open-label trial enrolled subjects with advanced or recurrent, non-resectable HPV16-positive cervical cancer.
Nykode doses first participant in Phase I/II Covid-19 vaccine trial
The trial will analyse the safety, reactogenicity and immunogenicity of T cell-specific/VB10.2210 and the RBD/VB10.2129 vaccines.
BerGenBio concludes subject enrolment in Phase II AML drug trial
Bemcentinib plus LDAC was found to be efficacious and well-tolerated in relapsed elderly AML patients in a study.
How BerGenBio became a frontrunner in UK hunt for Covid-19 treatment
Norwegian biopharma firm BerGenBio is the first of six companies to have its potential Covid-19 treatment fast-tracked as part of…
ByBerGenBio reports positive results from first stage of NSCLC study
Norwegian biopharmaceutical company BerGenBio has reported positive results from the first stage of a Phase II trial (BGBC008) assessing the…